newsfilter
← Latest News
GlobeNewswire·

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

  • S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd.'s long-term issuer credit rating from BB+ to BBB- with a Stable outlook.
  • This upgrade joins recent improvements from Fitch & Moody's, granting Teva investment-grade credit ratings from all major agencies covering its debt.
  • Teva's Chief Financial Officer Eli Kalif attributed the upgrades to the successful execution of the "Pivot to Growth" strategy & progress in debt reduction.
  • S&P cited Teva's sustainable growth prospects driven by strong branded product execution, stabilized generics, & a pipeline of late-stage assets.
  • Teva continues its transformation into a leading innovative biopharmaceutical company with a world-class generics business.
  • The press release includes a cautionary note regarding forward-looking statements & potential risks that could cause actual results to differ from expectations.